Regeneron Pharmaceuticals, Inc.
REGN
$718.16
-$26.67-3.58%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -20.86% | 33.02% | 47.90% | -11.71% | -3.13% |
| Total Depreciation and Amortization | 11.86% | 15.46% | 17.07% | 14.67% | 12.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 351.11% | -155.43% | -1,002.17% | 12.66% | -398.53% |
| Change in Net Operating Assets | -40.72% | 66.77% | -1,017.47% | 82.86% | -116.07% |
| Cash from Operations | 15.89% | 15.88% | -65.38% | 10.60% | -36.64% |
| Capital Expenditure | 20.60% | -37.44% | -59.73% | 24.86% | -65.18% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -202.63% | 100.00% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 197.20% | -23.51% | 82.77% | -2,601.22% | 111.08% |
| Cash from Investing | 629.61% | -15.74% | 76.66% | -615.78% | 96.44% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -69.80% | -5.17% | 382.47% | 40.58% | -19.22% |
| Repurchase of Common Stock | -64.15% | -26.54% | -29.90% | 21.38% | -20.46% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -154.54% | -55.66% | 22.16% | 114.60% | -80.17% |
| Foreign Exchange rate Adjustments | -450.00% | 500.00% | 25.00% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -17.38% | -60.29% | 65.56% | -115.81% | 249.87% |
